This is an RSS newsfeed from BioMed Central It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit http://www.biomedcentral.com/info/about/rss/ Current Opinion in Investigational Drugs - Most viewed articles http://thomsoncurrentdrugs.com/products/journals/coidmostviewed/ Most viewed articles in last 30 days from Current Opinion in Investigational Drugs (ISSN 1472-4472) published by Current Drugs Limited. Apixaban, an oral, direct inhibitor of activated Factor Xa http://www.biomedcentral.com/1472-4472/9/1020 E Shantsila and GYH Lip Current Opinion in Investigational Drugs 2008, 9:1020-1033 Number of accesses: 71 2008-08-22 doi:10.1186/cd-937523 Current Opinion in Investigational Drugs 1472-4472 9 1020 2008-08-22 HDL: Still a target for new therapies? http://www.biomedcentral.com/1472-4472/9/950 SJ Nicholls Current Opinion in Investigational Drugs 2008, 9:950-956 Number of accesses: 57 2008-08-22 doi:10.1186/cd-937508 Current Opinion in Investigational Drugs 1472-4472 9 950 2008-08-22 Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes http://www.biomedcentral.com/1472-4472/9/402 CF Deacon Current Opinion in Investigational Drugs 2008, 9:402-413 Number of accesses: 56 2008-04-04 doi:10.1186/cd-893178 Current Opinion in Investigational Drugs 1472-4472 9 402 2008-04-04 Non-nucleoside inhibitors of the HCV NS5B polymerase: Progress in the discovery and development of novel agents for the treatment of HCV infections http://www.biomedcentral.com/1472-4472/8/614 PL Beaulieu Current Opinion in Investigational Drugs 2007, 8:614-634 Number of accesses: 50 2007-07-31 doi:10.1186/cd-817342 Current Opinion in Investigational Drugs 1472-4472 8 614 2007-07-31 ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases ABT-874, a fully human mAb that blocks the binding of IL-12 and IL-23 to their shared IL-12 receptor β1, is currently being developed by Abbott Laboratories for the potential treatment of Crohn's disease and psoriasis. The compound is currently in phase III clinical trials for psoriasis and phase II trials for Crohn's disease. ABT-87 was previously being developed for the potential treatment of multiple sclerosis; however, by May 2007, development for this indication was discontinued. http://www.biomedcentral.com/1472-4472/9/515 C Ding, J Xu and J Li Current Opinion in Investigational Drugs 2008, 9:515-522 Number of accesses: 46 2008-04-25 doi:10.1186/cd-899624 Current Opinion in Investigational Drugs 1472-4472 9 515 2008-04-25 Pulmonary arterial hypertension: On the way to a manageable disease http://www.biomedcentral.com/1472-4472/9/957 HAM Mucke Current Opinion in Investigational Drugs 2008, 9:957-962 Number of accesses: 45 2008-08-22 doi:10.1186/cd-937509 Current Opinion in Investigational Drugs 1472-4472 9 957 2008-08-22 The development of novel anti-hyperlipidemic drugs: A tough business gets tougher http://www.biomedcentral.com/1472-4472/9/945 BR Krause Current Opinion in Investigational Drugs 2008, 9:945-949 Number of accesses: 37 2008-08-22 doi:10.1186/cd-937507 Current Opinion in Investigational Drugs 1472-4472 9 945 2008-08-22 Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors http://www.biomedcentral.com/1472-4472/9/614 JA McCubrey, M Milella, A Tafuri, AM Martelli, P Lunghi, A Bonati, M Cervello, JT Lee and LS Steelman Current Opinion in Investigational Drugs 2008, 9:614-630 Number of accesses: 34 2008-05-28 doi:10.1186/cd-910547 Current Opinion in Investigational Drugs 1472-4472 9 614 2008-05-28 Raltegravir, an HIV-1 integrase inhibitor for HIV infection http://www.biomedcentral.com/1472-4472/9/885 C Cabrera Current Opinion in Investigational Drugs 2008, 9:885-898 Number of accesses: 29 2008-07-25 doi:10.1186/cd-928098 Current Opinion in Investigational Drugs 1472-4472 9 885 2008-07-25 Sirtuins: Novel targets for metabolic disease http://www.biomedcentral.com/1472-4472/9/371 PJ Elliott and M Jirousek Current Opinion in Investigational Drugs 2008, 9:371-378 Number of accesses: 28 2008-04-04 doi:10.1186/cd-893173 Current Opinion in Investigational Drugs 1472-4472 9 371 2008-04-04